Jump Financial, LLC Allogene Therapeutics, Inc. Transaction History

Jump Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.08 - $3.5 $352,243 - $592,718	-169,348 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $345,761 - $679,119	155,050 Added 1084.42%	169,348 $394,000
Q1 2024 May 13, 2024	BUY	$2.92 - $5.63 $41,750 - $80,497	14,298 New	14,298 $63,000
Q1 2023 Oct 21, 2024	BUY	$4.92 - $8.21 $248,036 - $413,898	50,414 Added 29.77%	219,762 $1.09 Million
Q1 2023 May 03, 2023	BUY	$4.92 - $8.21 $547,167 - $913,058	111,213 Added 102.45%	219,762 $1.09 Million
Q4 2022 Feb 13, 2023	SELL	$5.62 - $11.11 $100,131 - $197,946	-17,817 Reduced 14.1%	108,549 $682,000
Q3 2022 Nov 07, 2022	BUY	$10.32 - $17.28 $1.3 Million - $2.18 Million	126,366 New	126,366 $1.37 Million
Q2 2022 Aug 09, 2022	SELL	$6.78 - $12.28 $887,366 - $1.61 Million	-130,880 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$7.65 - $15.29 $1 Million - $2 Million	130,880 New	130,880 $1.19 Million
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $954,230 - $1.44 Million	-37,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $933,880 - $1.61 Million	37,000 New	37,000 $934,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.